Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug - TheStreet
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology, Inc.
Amendment No. 2 to License Agreement dated October 29, 2020, | PUMA BIOTECHNOLOGY, INC. | Business Contracts | Justia
Puma Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. - PBYI
Puma Biotechnology Surging
PumaBiotech (@pumabiotech) / Twitter
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Millennium Management Llc discloses stake in PBYI / Puma Biotechnology Inc
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology
Puma Biotechnology
Should You Buy Puma Biotechnology Inc (PBYI) Stock After it Has Gained 6.09% in a Week?
